...
首页> 外文期刊>Materia Medica Polona >Doxazosin - Alpha- 1-Adrenergic Antagonists Drug in the Long-Term (3 years). Management of Benign Prostatic Hyperplasia
【24h】

Doxazosin - Alpha- 1-Adrenergic Antagonists Drug in the Long-Term (3 years). Management of Benign Prostatic Hyperplasia

机译:长期服用多沙唑嗪-α-1肾上腺素能拮抗剂(3年)。良性前列腺增生症的治疗

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

To evaluate the efficacy and tolerability of doxazosin in the long-term (3yr.) treatment of bladder outflow obstruction resulting from BPH. Data were obtained in 64 patients with BPH. The main outcome measures were urodynamic and symptomatic evaluation for efficacy. In the three year follow up study on doxazosin, including 33 patients remaining on the drug drug and 11 operated (total 44) and excluding those who abandoned the therapy or died, the positive effect of the treatment was found in 75 percent and failure in 25 percent of cases. Doxazosin was well-tolerated and produced both urodynamic and symptomatic improvement in men with BPH. Results from clinical trials demonstrate doxazosin is effective and safe and well tolerated in both normotensive and hypertensive patients with BPH.
机译:为了评估多沙唑嗪在长期(3年)治疗BPH引起的膀胱流出梗阻中的疗效和耐受性。获得了64例BPH患者的数据。主要结局指标为尿动力学和症状评估疗效。在多沙唑嗪的三年随访研究中,包括33名仍在使用该药物的患者和11名接受手术的患者(共44名),不包括那些放弃治疗或死亡的患者,发现该疗法的积极作用为75%,失败率为25%案件的百分比。多沙唑嗪具有良好的耐受性,并能改善BPH男性的尿动力学和症状改善。临床试验结果表明,多沙唑嗪在血压正常和高血压的BPH患者中均有效,安全且耐受性良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号